International practice patterns by age and severity of lung disease in cystic fibrosis: Data from the Epidemiologic Registry of Cystic Fibrosis (ERCF)

Pediatric Pulmonology

Volumn 24, Issue 2, 1997, Pages 147-154

  Koch, Christian ^a   McKenzie, Sheila G ^b   Kaplowitz, Haley ^c   Hodson, Margaret E ^d   Harms, H Karsten ^e   Navarro, Jean ^f   Mastella, Gianni ^g  

^a Rigshospitalet   (Denmark)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c GENENTECH INC   (United States)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g Cystic Fibrosis Center   (Italy)

Author keywords

Cystic fibrosis; Diabetes mellitus; Nasal polyps; Pulmonary function; Treatment

Indexed keywords

ACETYLCYSTEINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DORNASE ALFA; EXPECTORANT AGENT; INSULIN; MUCOLYTIC AGENT; ORAL ANTIDIABETIC AGENT; PANCREAS ENZYME;

ADOLESCENT; BRONCHODILATATION; CHILD; CLINICAL PRACTICE; CONFERENCE PAPER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DRUG CHOICE; FUNCTIONAL ASSESSMENT; HUMAN; INFANT; LUNG FUNCTION; MAJOR CLINICAL STUDY; NUTRITIONAL SUPPORT; PATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; CHILD; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DRUG UTILIZATION; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES;

EID: 0030831975     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199708)24:2<147::AID-PPUL15>3.0.CO;2-2     Document Type: Conference Paper

References (10)

1. Bush A. Cardiopulmonary physiology. In: Hodson ME, Geddes DM, eds. Cystic Fibrosis. London: Chapman & Hall, 1995:151-177.
2. Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet. 1993; 341:1065-1069.
3. Nikolaizik WH, Schöni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr. 1996; 128:271-274.
4. Lanng S, Hansen A, Thorsteinsson B, Nerup J. Glucose tolerance in patients with cystic fibrosis: a five year prospective study. BMJ. 1995; 311:655-659.
5. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, Klein DJ. Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988; 112:373-377.
6. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992; 151:684-687.
7. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Karkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993; 148:145-151.
8. Ranasinha C, Assoufi B, Shak S, Christianson D, Fuchs H, Empey D, Geddes D, Hodson M. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I (rhDNase) in adults with stable stage cystic fibrosis. Lancet. 1993; 342:199-202.
9. Fuchs HJ, Borowitz DH, Christiansen ED, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Eng J Med. 1994; 331:637-642.
10. Corey M, McLaughlin J, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988; 41: 583-591.